FDA Announces Guidance for Developing Drugs and Biologics for BCG-Resistant Nonmuscle Invasive Bladder Cancer

Summary

The FDA has finalized a guidance for industry to help develop treatments for patients with a rare form of bladder cancer that is resistant to current therapies, addressing an unmet medical need.